Biosimilars Forum Urges Equal Access For US Humira Rivals
Executive Director Julie Reed Calls For Availability As Adalimumab Biosimilars Launch
With the US on the cusp of biosimilar competition to Humira, Julie Reed – executive director of the country’s Biosimilars Forum – has urged PBMs to bolster access by making all adalimumab biosimilars available as they launch throughout 2023.
You may also be interested in...
United Health's pharmacy benefit manager outlined plans for early inclusion of up to three biosimilar versions of adalimumab on its formularies in 2023, at parity to the brand.
As the biosimilars industry awaits several US adalimumab launches in 2023, Organon has set out the reasons why it believes it can stand out from its competitors.
In an exclusive interview with Generics Bulletin, the Biosimilars Forum’s executive director Julie Reed sets out the group’s priorities and explains how its diverse membership is helping to position it as a leading voice for the US biosimilars industry.